Combined Chronic Toxicity/Carcinogenicity Studies (OECD TG 451-3)

Tg
{"title":"Combined Chronic Toxicity/Carcinogenicity Studies (OECD TG 451-3)","authors":"Tg","doi":"10.1787/9789264304741-24-en","DOIUrl":null,"url":null,"abstract":"745. These assays determine the general toxicity (OECD TG 452 and TG 453) and carcinogenicity (OECD TG 451 and TG 453) of chemicals in laboratory animals after exposure for a period lasting most of the lifespan. Route of administration may be oral, dermal or inhalation, although oral via diet is the most common. OECD TG 453 was revised in September 2009 and replaced OECD TG 451 (older studies may have used OECD TG 451). General toxicity studies usually have a duration of 12 months whilst carcinogenicity studies usually have a duration of 18 or 24 months depending on the species tested. They provide information on major toxic effects, target organ toxicity and carcinogenicity. Although they have not been validated for the detection of endocrine disruptors (EDs), they contain many endpoints that are suitable for the determination of endocrine effects. Organ weights are not always included in the carcinogenicity phases of these studies as neoplastic changes may confound them, but they are generally determined at 12 months. A comparison can be made with validation of the OECD TG 407 (28-Day Oral Toxicity Study) for endocrine endpoints (OECD, 2006) where substances that were moderate and strong EDs for (anti)estrogenicity and (anti)androgenicity (e.g. ethinylestradiol and flutamide) and weak and strong modulators of thyroid hormone-related effects (e.g. propylthiouracil, T4 and methyl testosterone) were detected. Steroidogenesis inhibition was also detected although only one (potent) chemical was used in the validation study (CGS 18320B). OECD TG 453 and TG 452 are likely to be more sensitive than OECD TG 407 because of the extended dosing period and the larger number of animals per group (20 or 50 rodents per sex per group for chronic or carcinogenicity studies respectively compared with 5 in OECD TG 407). OECD TG 453 and TG 452, however, do not contain some sensitive endpoints (e.g. thyroid hormones, estrous cyclicity) that may be included in OECD TG 407.","PeriodicalId":19458,"journal":{"name":"OECD Series on Testing and Assessment","volume":"83 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OECD Series on Testing and Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1787/9789264304741-24-en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

745. These assays determine the general toxicity (OECD TG 452 and TG 453) and carcinogenicity (OECD TG 451 and TG 453) of chemicals in laboratory animals after exposure for a period lasting most of the lifespan. Route of administration may be oral, dermal or inhalation, although oral via diet is the most common. OECD TG 453 was revised in September 2009 and replaced OECD TG 451 (older studies may have used OECD TG 451). General toxicity studies usually have a duration of 12 months whilst carcinogenicity studies usually have a duration of 18 or 24 months depending on the species tested. They provide information on major toxic effects, target organ toxicity and carcinogenicity. Although they have not been validated for the detection of endocrine disruptors (EDs), they contain many endpoints that are suitable for the determination of endocrine effects. Organ weights are not always included in the carcinogenicity phases of these studies as neoplastic changes may confound them, but they are generally determined at 12 months. A comparison can be made with validation of the OECD TG 407 (28-Day Oral Toxicity Study) for endocrine endpoints (OECD, 2006) where substances that were moderate and strong EDs for (anti)estrogenicity and (anti)androgenicity (e.g. ethinylestradiol and flutamide) and weak and strong modulators of thyroid hormone-related effects (e.g. propylthiouracil, T4 and methyl testosterone) were detected. Steroidogenesis inhibition was also detected although only one (potent) chemical was used in the validation study (CGS 18320B). OECD TG 453 and TG 452 are likely to be more sensitive than OECD TG 407 because of the extended dosing period and the larger number of animals per group (20 or 50 rodents per sex per group for chronic or carcinogenicity studies respectively compared with 5 in OECD TG 407). OECD TG 453 and TG 452, however, do not contain some sensitive endpoints (e.g. thyroid hormones, estrous cyclicity) that may be included in OECD TG 407.
慢性毒性/致癌性联合研究(OECD TG 451-3)
745. 这些试验确定了化学物质在实验动物的大部分生命周期内暴露后的一般毒性(OECD TG 452和TG 453)和致癌性(OECD TG 451和TG 453)。给药途径可能是口服、皮肤或吸入,但最常见的是通过饮食口服。OECD TG 453于2009年9月修订,取代OECD TG 451(较早的研究可能使用OECD TG 451)。一般毒性研究通常需要12个月的时间,而致癌性研究通常需要18或24个月的时间,这取决于测试的物种。它们提供了关于主要毒性作用、靶器官毒性和致癌性的信息。虽然它们尚未被验证用于检测内分泌干扰物(EDs),但它们包含许多适合测定内分泌影响的终点。器官重量并不总是包括在这些研究的致癌性阶段,因为肿瘤改变可能会混淆它们,但它们通常在12个月时确定。可以与经合组织tg407(28天口服毒性研究)对内分泌终点的验证进行比较(经合组织,2006年),其中检测到具有(抗)雌激素性和(抗)雄激素性的中度和强ed物质(如炔雌醇和氟他胺)以及甲状腺激素相关作用的弱和强调节剂(如丙硫脲嘧啶、T4和甲基睾酮)。虽然在验证研究中只使用了一种(有效的)化学物质(CGS 18320B),但也检测到类固醇生成抑制作用。经合组织TG 453和TG 452可能比经合组织TG 407更敏感,因为给药期更长,每组动物数量更多(在慢性或致癌性研究中,每组每性别20或50只啮齿动物,而经合组织TG 407为5只)。然而,经合组织TG 453和TG 452不包含经合组织TG 407中可能包含的一些敏感终点(如甲状腺激素、发情周期)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信